



Bari International Conference

Bari • Italy • 3-5 October 2014

Villa Romanazzi Carducci Conference Center

Venue

Villa Romanazzi Carducci Conference Center, Bari, Italy
Nearby Hotels have been blocked by the Organizing Secretariat.
Please contact congress@smc-media.com

Continuing Medical Education

BIC has been accredited for Italian CME: event n. 99217 (14.3 credits). European CME accreditation pending. US accreditation will be requested as soon as a sufficient number of registrations from USA are received. Please contact SMC media for further information.

Provider

Congress Team Srl is the Italian CME provider.

Organizing Secretariat

SMC media Srl • Milan, Italy
+39 0283419430.1 • 0258102846 • info@smc-media.com • congress@smc-media.com

Sponsors



Social Events

Do not miss the Competition Event and Social Dinners

SIGN UP to receive program updates
and news on BIC upcoming social events at

www.bic2014.org

10/06/2014

Preliminary Program

... traditionally advanced

Abstract deadline 30th May

Early Registration

www.bic2014.org


Once every 3 years,
the BIC meeting is organized
in the Apulia region of Italy
with the aim of providing a
3-day full-immersion
into the newest research

Scientific Committee

P.M. Mannucci, *Chairman*

F. Peyvandi, *Co-Chair*

N. Ciavarella • A.B. Federici • M.E. Mancuso • E. Santagostino



Friday, 3rd October

SESSION 1 • Hemophilia

- 8:30 _New insights into the structure and function of factor VIII. **P. Lenting** (France)
- 9:00 _Factor VIII physiology and von Willebrand factor interaction: consequences for half-life and bioengineering. **S.W. Pipe** (USA)
- 9:30 _Personalized medicine in hemophilia: how global assays can support individualization of factor therapy. **G. Young** (USA)
- 10:00 _Potential interest of global hemostasis assays in the management of hemophilia patients with inhibitors. **Y. Dargaud** (France)
- 10:30 _Thrombosis in patients with inherited bleeding disorders. **M. Makris** (UK)
- 11:00 break

SESSION 2 • Rare bleeding disorders: no longer orphan diseases

- 11:30 _New insights in the treatment of parahemophilia. **P. Simioni** (Italy)
- 12:00 _Factor V deficiency and development of an orphan drug. **F. Peyvandi** (Italy)
- Lunch (12:30-14:00)

SPECIAL LECTURE

- 14:00 _How coagulation may differ in hemostasis and thrombosis. **Z.M. Ruggeri** (USA)

Satellite Symposia and Lectures

- 14:30 • Kedrion (program to be announced)
- 15:30 • CSL Behring (program TBA)
- 16:00 • Novo Nordisk (program TBA)
- 16:30 break

SESSION 3 • Complement activation and microvascular/macrovacular thrombosis

- 17:00 _Disturbances of complement regulation in thrombotic microangiopathies. **S. Meri** (Finland)
- 17:30 _The role of complement activation in the diagnosis, treatment, and follow up of thrombotic thrombocytopenic purpura (TTP) and atypical hemolytic-uremic syndrome (aHUS). **S.Cataland** (USA)
- 18:00 _Thrombosis and paroxysmal nocturnal hemoglobinuria (PNH). **Anita Hill** (UK)
- 18:30 _Complement activation-related diseases: shiga toxin hemolytic-uremic syndrome (Stx-HUS), atypical hemolytic-uremic syndrome (aHUS) and thrombotic thrombocytopenic purpura (TTP). **M. Galbusera** (Italy)

Saturday, 4th October

SESSION 4 • Von Willebrand disease

- 8:30 _The philosophy of VWD. **I. Peake** (UK)
- 9:00 _The reality of VWD. **A. Goodeve** (UK)
- 9:30 _The role of blood outgrowth endothelial cells in understanding VWD. **P. James** (Canada)
- 10:00 _Ascertaining and defining variant VWD. **R.R. Montgomery** (USA)
- 10:30 break
- 11:00 _Clinical evaluation of a novel point of care test to determine different types of VWD in whole blood. **M. Roest** (The Netherlands)
- 11:30 _Predictors of bleeding and replacement therapy in VWD. **A.B. Federici** (Italy)

SPECIAL LECTURE

- 12:00 _Fibrin clot structure and function: mechanisms of clot stability and thrombosis. **R.A.S. Ariens** (UK)

Lunch (12:30-14:00)

Satellite Symposia and Lectures

- 14:00 • Grifols (program TBA)
- 14:30 • Sobi (program TBA)
- 15:30 • Joint Lecture of Grifols, Kedrion and LFB (program TBA)

SESSION 5 • Von Willebrand factor in hemostasis and thrombosis

- 16:00 _Receptor mediated clearance of von Willebrand factor and factor VIII. **L. Swystun** (Canada)
- 16:30 _New insights into the age-related pathobiology of von Willebrand factor. **D. Lillicrap** (Canada)
- 17:00 break
- 17:30 _Von Willebrand factor: cigars, strings and beyond. **J.C.J. Eikenboom** (The Netherlands)
- 18:00 _Von Willebrand factor control of blood vessel formation. **A.M. Randi** (UK)
- 18:30 _Role of von Willebrand factor in thromboembolism. **R. Schneppenheim** (Germany)
- 19:00 _Von Willebrand factor and the risk of atherothrombosis. **F.W.G. Leebeek** (The Netherlands)
- 19:30 _Clinical aspects of active von Willebrand factor. **M. Roest** (The Netherlands)

Sunday, 5th October

SESSION 6 • Gene therapy in bleeding disorders

- 8:30 _Update on gene therapy for hemophilia. **A. Nathwani** (UK)
- 9:00 _Overcoming immunogenicity of AAV vectors in gene therapy for inherited bleeding disorders. **F. Mingozzi** (France)
- 9:30 _Lentiviral vector based gene therapy of hemophilia. **L. Naldini** (Italy)
- 10:00 _Non-viral gene therapy for VWD using the Sleeping-Beauty transposon. **S. De Meyer** (Belgium)
- 10:30 _Invited discussant. **P. Simioni** (Italy)
- 11:00 break

ORAL COMMUNICATIONS (11:30-13:00)

Lunch (13:00-14:00)

Satellite Symposium

- 14:00 • Baxter (program TBA)

SESSION 7 • Von Willebrand factor and ADAMTS-13 in health and disease

- 15:00 _Thrombotic microangiopathies: important open research questions. **B. Lämmle** (Switzerland)
- 15:30 _Structure, regulation and biological function of ADAMTS-13. **E. Sadler** (USA)
- 16:00 _Interplay between von Willebrand factor and ADAMTS-13 in vitro and in vivo. **K. Vanhoorelbeke** (Belgium)
- 16:30 break
- 17:00 _Von Willebrand factor and ADAMTS-13 in various disease processes. **D.D. Wagner** (USA)
- 17:30 _Novel therapeutics for acquired thrombotic thrombocytopenic purpura (TTP). **L. Zheng** (USA)
- 18:00 _Insights into acquired ADAMTS-13 deficiency. **J.A. Kremer Hovinga** (Switzerland)
- 18:30 _Acquired thrombotic thrombocytopenic purpura (TTP): how far to prevent relapses? **P. Coppo** (France)

